China Biologic Products, Inc. one of the leading plasma-based pharmaceutical companies in the PRC has announced that the company began its annual maintenance of its production facilities on July 25, 2008.
The maintenance period will last for one month, during which time production at the manufacturing facilities will be suspended. During the required maintenance period, the Company will conduct any required major maintenance of its production equipment to ensure the efficiency and safety of subsequent production. The Company will also take advantage of the maintenance period to train its staff, and allow them to take proper vacation time as required by Chinese labor laws.
In addition, since the manufacturing process of compression and filtration in cold ethanol fractionation for human plasma albumin and immunoglobulin related products requires a constant low temperature, CBP has carefully planned its maintenance period to fall during the hottest days of summer in order to conserve energy and curtail expenses related to the recent increases in fuel costs.
CBP reports that it has sufficient product inventories on hand to meet market demand during the maintenance period. In addition, operation of the company's plasma collection stations will continue as usual to ensure that the manufacturing facilities can resume their normal operations at the end of the maintenance period.
"We chose to conduct the maintenance period in the summer when production costs are usually at the highest," said Chao Ming Zhao, the CEO of CBP. "The annual routine maintenance of our manufacturing facilities is not expected to affect our sales revenue in the third quarter, as we have stocked sufficient inventories to meet our projected demand."
Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products for hospitals and other health care facilities in China. The company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.